Gustavo Viani, Associate Professor at Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared on LinkedIn:
“Proton Therapy Beats Photons in Pediatric Medulloblastoma – More Life, Less cost!
Grateful to my team Helio Salmon, Carlos Eduardo Cardoso, Gustavo Oliveira do Amaral. Excited to share our new study: proton therapy for pediatric medulloblastoma in Brazil is more effective, less costly and improves survival.
Gap Addressed.
Access to proton therapy is absent in Brazil, and robust economic evaluations from a payer perspective for pediatric medulloblastoma have been lacking.
Key Results:
• Model: Markov, 30-year horizon.
• Effectiveness:
• Protons to 20.45 QALYs at US$102,933.
• Photons to 16.87 QALYs at US$141,971.
• ICER: –US$22,857/QALY to Protons are dominant (more effective + less costly).
• Sensitivity Analysis:
• Protons cost-effective in more than 95 % of simulations.
• Mean Net Monetary Benefit = US$70,290.
• Survival at 30 years:
• 40.5 % with protons.
• 27.1 % with photons.
Take-Home Message
For children with medulloblastoma, proton radiotherapy is a cost-effective, dominant strategy that provides better outcomes and lower lifetime costs.
Policymakers and insurers should prioritize expanding access to this technology.”
More posts featuring Gustavo Viani.